

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 61775

Title: Trends in the management of infectious disease under severe acute respiratory syndrome coronavirus 2 era: From pathophysiological comparison of COVID-19 and influenza

Reviewer's code: 04092118

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Postdoc, Senior Lecturer

Reviewer's Country/Territory: Romania

Author's Country/Territory: Japan

Manuscript submission date: 2020-12-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-12-20 10:57

Reviewer performed review: 2020-12-20 11:11

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

I have read with great interest the manuscript entitled "Trends in the management of infectious disease under SARS-CoV-2 era: From pathophysiological comparison of COVID-19 and influenza". The paper submitted as a mini-review covers a hot topic and discusses epidemiology, pathogenesis, treatment and prevention features of SARS-CoV-2 versus influenza virus. At a glance, the paper needs more substantiation. When doing a comparison, in order to capture the readers' attention, numbers or graphs are needed. Organizing the main differences between the two viruses in a table would be a plus. Pathogenesis needs more details, as the literature is abundant in this respect. Also, treatment paragraph needs an update: "As of this writing, remdesivir is the first drug to be used that acts against the virus itself, and is showing good efficacy. We also look forward to the appearance of other antiviral drugs, such as favipiravir" – there is new data available on this topic. Not least, a more detailed approach on prevention by vaccination would be advised.